Natalizumab - Biogen/Perrigo

Drug Profile

Natalizumab - Biogen/Perrigo

Alternative Names: AN 10022; AN 100226; Antegren; Anti-alpha4 integrin monoclonal antibody; BG-00002; BG-0002; BG-0002-E; Tysabri

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Corporation
  • Developer Biogen; Biogen Idec; Elan Corporation; Perrigo
  • Class Antineoplastics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Multiple sclerosis
  • Phase II Epilepsy; Graft-versus-host disease; Stroke
  • Discontinued Multiple myeloma; Rheumatoid arthritis

Most Recent Events

  • 04 Apr 2018 Biogen has patent protection for natalizumab in USA and Europe
  • 07 Feb 2018 Adverse events and therapeutic trial data from the phase II ACTION2 trial in acute ischemic Stroke released by Biogen
  • 20 Nov 2017 Biogen completes the phase II ACTION II trial for Stroke in Germany, Spain, United Kingdom, USA (IV) (NCT02730455)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top